Stable protein compositions and methods of their use
The present invention is directed to compositions and methods for stabilizing a protein without a surfactant. The present invention is further directed to compositions comprising a protein and at least one excipient selected from the group consisting of hindered amines, anionic aromatics, functionalized amino acids, oligopeptides, low molecular weight aliphatic polyacids, zwitterions, phospholipids, cyclodextrins, polyethylene glycols, gelatins, urea, ethanol, glycerin, dextran, xanthan gum, 2-(2-ethoxyethoxy)ethanol, hydroxypropyl cellulose, propylene glycol, a short-chain organic acid, deoxycholate, sodium nitrate, sodium sulfate, proline and lysine.
1. A stable adalimumab composition comprising:
(i) about 25 mg/mL to about 120 mg/mL adalimumab or a biosimilar thereof;
(ii) about 5 mM to about 50 mM of a buffer;
(iii) about 10 mM to about 300 mM of an amino acid; and
(iv) at least one excipient selected from the group consisting of:
about 10 mM to about 150 mM of a cyclodextrin;
about 0.1% w/v to about 5% w/v of a cellulose derivative;
about 1% w/v to about 2% w/v of a polyethylene glycol; and
a salt present at a concentration of less than 50 mM,
wherein the composition is free of surfactant, and the composition is stable at a temperature of 25° C. for two weeks or at a temperature of 40° C. for one week.
2. The composition of claim 1 , wherein the composition is free or substantially free of polyol.
3. The composition of claim 1 , wherein the cyclodextrin is an alpha cyclodextrin, beta cyclodextrin, gamma cyclodextrin, or combinations thereof.
4. The composition of claim 3 , wherein the alpha cyclodextrin, beta cyclodextrin, or gamma cyclodextrin is a derivatized cyclodextrin.
5. The composition of claim 4 , wherein the derivatized beta cyclodextrin comprises: methyl-beta-cyclodextrins (“MβCD”), randomly methylated-beta-cyclodextrin (“RMβCD”), Sulfobutylether-beta-cyclodextrins (“SBEβCD”), or hydroxypropyl-beta-cyclodextrins (“HPβCD”).
6. The composition of claim 5 , wherein the derivatized beta cyclodextrin is HPβCD.
7. The composition of claim 6 , wherein HPβCD is present at a concentration of about 25 mM to about 100 mM.
8. The composition of claim 1 , wherein the at least one excipient comprises at least two polyethylene glycols.
9. The composition of claim 8 , wherein each of the at least two polyethylene glycols have a molecular weight from 200 daltons to 20 kilodaltons.
10. The composition of claim 1 , wherein adalimumab or a biosimilar thereof is present at a concentration of about 50 mg/mL to about 100 mg/mL.
11. The composition of claim 1 , wherein the composition has a pH of about 4 to about 5.
12. The composition of claim 1 , wherein the composition exhibits long term stability.
13. The composition of claim 1 , wherein the composition is a pharmaceutical composition.
14. The composition of claim 13 , wherein the composition is a liquid composition.
15. The composition of claim 14 , wherein the liquid composition is suitable for administration to a subject.
16. The composition of claim 1 , wherein the composition is isotonic or has an osmolality of about 180 to about 420 mOsM.
17. The composition of claim 1 , wherein the composition has a conductivity of greater than 2.5 mS/cm.
18. The composition of claim 1 , wherein the composition comprises a salt at a concentration of less than 50 mM.
19. The composition of claim 1 , wherein the buffer comprises phosphate, pyrophosphate, citrate, acetate, glutamate, gluconate, histidine, succinate, adipate, maleate, tartrate, or combinations thereof.
20. The composition of claim 19 , wherein the buffer is histidine.
21. The composition of claim 20 , wherein the histidine buffer is present at a concentration of about 10 mM to about 30 mM.
22. The composition of claim 1 , further comprising a polyol.
23. The composition of claim 18 , wherein the salt comprises NaCl, KCl, Na 2 SO 4 , MgCl 2 , CaCl 2 , or adipate.
24. The composition of claim 23 , wherein the salt is present at a concentration of less than 28 mM.
25. The composition of claim 1 , wherein the amino acid is selected from the group consisting of histidine, glycine, methionine, serine, proline, and arginine, and combinations thereof.
26. A stable adalimumab composition comprising:
(i) about 25 mg/mL to about 120 mg/mL adalimumab or a biosimilar thereof;
(ii) about 5 mM to about 50 mM of a buffer;
(iii) about 10 mM to about 300 mM of an amino acid; and
(iv) at least one excipient selected from the group consisting of:
about 10 mM to about 150 mM of a cyclodextrin;
about 0.1% w/v to about 5% w/v of a cellulose derivative;
about 1% w/v to about 2% w/v of a polyethylene glycol; and
a salt present at a concentration of less than 50 mM,
wherein the composition is free of surfactant; and the composition has stability comparable to or better than a composition comprising adalimumab or a biosimilar thereof and surfactant, and the composition is stable at a temperature of 25° C. for two weeks or at a temperature of 40° C. for one week.
27. A stable pharmaceutical composition comprising:
(i) about 25 mg/mL to about 120 mg/mL adalimumab or a biosimilar thereof;
(ii) about 5 mM to about 50 mM of a buffer;
(iii) about 10 mM to about 300 mM of an amino acid; and
(iv) about 10 mM to about 150 mM HPβCD;
wherein the composition is free of surfactant, and the composition is stable at a temperature of 25° C. for two weeks or at a temperature of 40° C. for one week.
28. The composition of claim 27 , wherein the composition is free or substantially free of polyol.
29. The composition of claim 27 , wherein the adalimumab or biosimilar thereof is present at a concentration of about 50 mg/mL to about 100 mg/mL.
30. The composition of claim 27 , wherein HPβCD is present at a concentration of about 25 mM to about 100 mM.
31. The composition of claim 27 , wherein the composition has a pH of about 5 to about 6.
32. The composition of claim 27 , wherein the composition exhibits long term stability.
33. The composition of claim 27 , wherein the composition is suitable for administration to a subject.
34. The composition of claim 27 , wherein the composition is isotonic or has an osmolality of about 180 to about 420 mOsM.
35. The composition of claim 27 , wherein the composition has a conductivity of greater than 2.5 mS/cm.
36. The composition of claim 27 , wherein the composition further comprises a salt at a concentration of less than 50 mM.
37. The composition of claim 27 , wherein the buffer comprises phosphate, pyrophosphate, citrate, acetate, glutamate, gluconate, histidine, succinate, adipate, maleate, tartrate, or combinations thereof.
38. The composition of claim 37 , wherein the buffer is histidine.
39. The composition of claim 38 , wherein the histidine buffer is present at a concentration of about 10 mM to about 30 mM.
40. The composition of claim 27 , wherein the composition is (a) free of citrate buffer; or (b) free of phosphate buffer; or (c) free of a buffer composition comprising citrate buffer and phosphate buffer.
41. The composition of claim 27 , further comprising a polyol.
42. The composition of claim 36 , wherein the salt comprises NaCl, KCl, Na 2 SO 4 , MgCl 2 , CaCl 2 , or adipate.
43. The composition of claim 42 , wherein the salt is present at a concentration of less than 28 mM.
44. The composition of claim 27 , wherein the amino acid is selected from the group consisting of histidine, glycine, methionine, serine, proline, and arginine, and combinations thereof.